Ibrutinib and Venetoclax for First-Line Treatment of CLL
The University of Texas MD Anderson Cancer Center
Indexed incrossrefpubmed
Abstract
Background
Ibrutinib, an inhibitor of Bruton's tyrosine kinase, and venetoclax, an inhibitor of B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic leukemia (CLL). Preclinical investigations have indicated potential synergistic interaction of their combination.
Methods
).
Citation impact
499
total citations
- FWCI
- 48.03
- Percentile
- 100%
- References
- 27
Citations per year
Authors
32- NJNitin JainCorresponding
The University of Texas MD Anderson Cancer Center
- MJMichael J. Keating
The University of Texas MD Anderson Cancer Center
- PAPhilip A. Thompson
The University of Texas MD Anderson Cancer Center
- AFAlessandra Ferrajoli
The University of Texas MD Anderson Cancer Center
- JAJan A. Burger
The University of Texas MD Anderson Cancer Center
Topics & keywords
Topics
Keywords
- Ibrutinib
- Venetoclax
- Chronic lymphocytic leukemia
- Medicine
- Bruton's tyrosine kinase
- Lymphoma
- Cancer research
- Leukemia
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.